Rejuvenation & Regeneration

This field asks whether aging cells and damaged tissues can be made to function more like younger ones. Two major approaches are removing senescent cells—often nicknamed “zombie cells”—that no longer work properly but remain active, and partially reprogramming older cells to restore more youthful patterns of function without erasing their identity.

Aging involves multiple forms of cellular damage, dysfunction, and loss of biological resilience. If medicine can safely clear, repair, reprogram, or replace damaged cells and tissues, it may slow—or partially reverse—some forms of age-related decline.

That would directly support the broader goal of Longevity Escape Velocity: reaching a point where advances across multiple medical fields extend healthy lifespan faster than time passes.

• Senescent-cell clearance: Research and treatments designed to remove dysfunctional senescent cells.
• Partial cellular reprogramming: Approaches that aim to restore youthful cell function without causing cells to lose their identity.
• Tissue regeneration: Progress in repairing or rebuilding damaged tissues and organs.
• Translation to humans: Replicated results moving from cell cultures and animal models toward credible human trials.

• An isolated cell-culture result with no independent replication or follow-up.
• Animal findings presented without a credible path toward human relevance.
• Company announcements or marketing claims that provide no underlying study data.
• Improvements in a single biomarker without evidence of meaningful functional benefit.

• Safety: Reprogramming cells too aggressively may cause loss of cell identity or uncontrolled growth, including cancer.
• Replication: Promising results must be reproduced by independent research groups.
• The species gap: Results in mice and other animal models frequently fail to translate to humans.
• Clinical timelines: Trials measuring age-related decline require meaningful endpoints, sufficient follow-up, and often many years of observation.

Highest ceiling of any field: partial epigenetic reprogramming is the only approach that has reversed multiple hallmarks of aging simultaneously in an animal. 2006 score of 12 marks the year the Yamanaka factors were published, with SENS newly proposed and senolytics not yet discovered. Today's 40 reflects a field with spectacular animal data, unsolved teratoma and dedifferentiation safety, no whole-organism delivery route, and a most-clinically-advanced sub-branch (senolytics) that has produced mixed-to-negative human readouts.

This assessment does not predict when—or whether—a specific rejuvenation therapy will reach patients. It is a provisional reading of the field’s overall research momentum, translational progress, and remaining barriers.

It should be treated as an evolving signal, not a clinical forecast or guaranteed roadmap.